Boosting CAR T-cell Efficacy to Increase Cancer Cure Rates
Aleta Biotherapeutics is using its novel technology platform to develop bespoke, multi-antigen-targeting biologics for a diverse range of indications, including B-cell cancers and solid tumors, improving outcomes in patient populations with high unmet need.